Related Articles
Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines
MEK inhibitors against MET-amplified non-small cell lung cancer
Determination of EGFR and KRAS mutational status in Greek non‑small‑cell lung cancer patients
Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS